Brickell Biotech completes Phase 3 tests for excessive sweating treatment
BOULDER — Clinical-stage pharmaceutical company Brickell Biotech Inc. (Nasdaq: BBI) announced Monday that the final patients had completed Phase 3 of the studies evaluating Brickell’s excessive sweating treatment.
Brickell expects to announce the results of the studies in the fourth quarter of 2021, with a new drug application submitted to the U.S. Food and Drug Administration in mid-2022.
The company’s treatment, a topical gel called sofpironium bromide, is designed to block the chemical that transmits signals that activate the sweat glands. It is already approved in Japan under the brand name Ecclock.
SPONSORED CONTENT
About 15 million people suffer from excessive sweating worldwide, according to the news release.
© 2021 BizWest Media LLC
BOULDER — Clinical-stage pharmaceutical company Brickell Biotech Inc. (Nasdaq: BBI) announced Monday that the final patients had completed Phase 3 of the studies evaluating Brickell’s excessive sweating treatment.
Brickell expects to announce the results of the studies in the fourth quarter of 2021, with a new drug application submitted to the U.S. Food and Drug Administration in mid-2022.
The company’s treatment, a topical gel called sofpironium bromide, is designed to block the chemical that transmits signals that activate the sweat glands. It is already approved in Japan under the brand name Ecclock.
About 15 million people suffer from excessive sweating worldwide, according to…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
